3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
26
Paclitaxel
22
Oxaliplatin
20
Nivolumab
16
Docetaxel
16
Capecitabine
16
Cisplatin
15
Fluorouracil
11
Cyclophosphamide
11
fludarabine
10
S 1 (combination)
10
Trastuzumab
9
Irinotecan
9
Carboplatin
8
Leucovorin
7
tislelizumab
6
aldesleukin
5
Ramucirumab
5
Interleukin-2
5
Gemcitabine
5
Drug Therapy
5
Bevacizumab
5
sintilimab
4
fludarabine phosphate
4
apatinib
4
Radiotherapy
4
Everolimus
4
regorafenib
3
olaparib
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Stomach Neoplasms
×
utomilumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts